Is Predictive Toxicology the Fast Track to Safe Drugs?
Add bookmark
Is Predictive Toxicology the Fast Track to Safe Drugs?
Add bookmarkUnexpected toxicity is the single biggest cause of pipeline attrition. Dr. Thomas Steger-Hartmann, Head of Investigational Toxicology at Bayer Healthcare, spoke to Andrea Charles from Pharma IQ, about the strategies medicinal chemists are increasingly attempting to avoid toxicological risk and how companies are enhancing their prediction capabilities. Steger-Hartmann also gives us an insider's view on how the Innovative Medicines Initiative (IMI) is working to speed up the development of better and safer medicines for patients.
[inlinead]
Tags:
Thomas Steger-Hartmann
Bayer Schering Pharma
Predictive Toxicology
genetic toxicology
early and mechanistic toxicology
laboratory diagnostics
pipeline attrition
Innovative Medicines Initiative
IMI
Bayer Healthcare
toxicological risk
